Candidates: VBI-2900 program consisting of two vaccines, VBI-2901 and VBI-2902
Types: VBI-2901 is a trivalent pan-coronavirus vaccine candidate expressing SARS-CoV-2, SARS-CoV (severe acute respiratory syndrome or SARS), and MERS-CoV (Middle East respiratory syndrome or MERS) spike proteins on the same particle. VBI-2902 is a monovalent vaccine candidate expressing the SARS-CoV-2 spike protein. The multivalent vaccine candidate program is based on VBI’s virus-like particle (eVLP) platform technology.
Status: VBI Vaccines said August 27 that it selected VBI-2901 and VBI-2902—both of which have the potential to be one-dose vaccines—for study in an adaptive Phase I/II human clinical study that is expected to start “around year-end 2020,” subject to regulatory approval.
The selection followed positive results in preclinical mouse studies conducted to enable selection of optimized clinical candidates. the studies evaluated antibody binding titers and neutralizing antibody titers across a number of vaccine constructs, in order to assess the impact of VBI’s proprietary eVLP platform vs. recombinant vaccine candidates, differences in the conformation of the spike protein, and a variety of adjuvants.
VBI said the preclinical data showed neutralizing antibody (nAb) activity, with convalescent sera from 20 individuals who had contracted and recovered from COVID-19 collected for comparison. After a single dose, VBI’s eVLPs expressing a stabilized pre-fusion form of the COVID-19 spike protein elicited a nAb GMT that was 4x higher than the GMT of high-titer convalescent sera, which increased to 64x higher after a second dose
The data also showed antibody binding (Ab) activity, as the same eVLPs also induced, after one dose, an Ab binding GMT that was 10x higher than both the GMT of high-titer convalescent sera and the GMT induced with a stabilized prefusion recombinant spike protein, VBI said.
A variety of adjuvants tested further improved the induction of nAb titers approximately 5-fold, and promoted strong Th1-type antibody and T cell responses, while the trivalent eVLP vaccine construct induced Ab binding titers across COVID-19, SARS, and MERS spike proteins in addition to broadening reactivity to a seasonal human coronavirus not expressed in the vaccine, VBI added.
VBI Vaccines has inked a manufacturing agreement with Therapure Biomanufacturing, the contract development and manufacturing organization (CDMO) division of Therapure Biopharma, for VBI’s coronavirus vaccine canddiates, Therapure said August 18. Therapure agreed to oversee the biomanufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at the Therapure facility in Mississauga, ON, where the company is based. The value of the agreement was not disclosed.
Earlier in August, Variation Biotechnologies, the Ottawa-based wholly-owned Canadian subsidiary of VBI Vaccines, said August 5 it was awarded up to C$56 million ($42.5 million) from the Strategic Innovation Fund of the Government of Canada to support development of the company’s coronavirus program, VBI-2900, through Phase 2 clinical studies.
“This funding will help accelerate our vaccine candidates into and through clinical development, the first clinical studies for which are expected to initiate by the end of 2020,” Jeff Baxter, VBI’s President and CEO, said in a statement.
In March, VBI agreed to partner with the National Research Council (NRC), Canada’s largest federal research and development organization. The collaboration will combine VBI’s viral vaccine expertise, eVLP technology platform, and coronavirus antigens with the NRC’s COVID-19 antigens and assay development capabilities.
The NRC and VBI agreed to evaluate and select the optimal vaccine candidate. Following IND-enabling preclinical studies conducted at both the NRC’s core facilities and VBI’s research facility in Ottawa, ON, VBI said it believes clinical study materials could be available in the fourth quarter.
“We believe the trivalent construct could allow for the production of broadly reactive antibodies, which offer potential for protection from mutated strains of COVID-19 that may emerge over time,” stated Francisco Diaz-Mitoma, MD, PhD, VBI’s chief medical officer.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: